Skip to content

Study · Observational study · n = 41 · 2017

2 results

Teriparatide Treatment in Elderly Patients With Sacral Insufficiency Fracture.

Yoo JI, Ha YC, Ryu HJ, Chang GW, Lee YK, Yoo MJ, Koo KH

The Journal of clinical endocrinology and metabolism1 Feb 2017Cited by 31 (Europe PMC)

PMID27880077 (opens in a new tab)DOI10.1210/jc.2016-3582 (opens in a new tab)PepBankPUB-27880077
Publisher pagePubMedAsk about this study
Jump to 2 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study2

2 results from studies that gave the peptide. 2 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In patients with sacral insufficiency fractures, time to mobilization was shorter with teriparatide than in controls.

    In plain wordsIn patients with sacral fractures, teriparatide treatment was linked to earlier movement than in controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    DecreaseTime to mobilization
    Study

    n = 41

    Comparator
    No teriparatide
    Outcome group
    Exercise and physical function · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneousAs given in this study (human).

    Measurements

    Mean time to mobilization
    1.2 weeks
    teriparatide
    Mean time to mobilization
    2 weeks
    controls

    Source sentences

    Summary
    The mean time to mobilization was 1.2 ± 0.4 weeks in patients who received teriparatide treatment, compared with 2.0 ± 0.3 weeks in controls (P < 0.001).
    3 context sentences
    Summary · context
    This retrospective, case-controlled, single center study, performed from 2009 to 2014, included 41 patients who underwent radiographs, magnetic resonance imaging, and/or bone scans to document sacral insufficiency fractures.
    Summary · context
    The intervention involved teriparatide at a once-daily subcutaneous dose of 20 μg within 2 days of hospital admission (21 patients).
    Summary · context
    Twenty patients (control group) did not receive teriparatide.
  2. 02HumanObservational studyEfficacy outcome

    In patients with sacral insufficiency fractures, all fractures in the teriparatide group had healed by 8 weeks, compared with 4 fractures in the control group.

    In plain wordsIn patients with sacral fractures, all fractures healed by 8 weeks with teriparatide, compared with 4 healed fractures in controls.

    Peptide
    Teriparatide (PTH 1-34)
    Outcome
    IncreaseFracture healing at 8 weeks
    Study

    n = 41

    Comparator
    No teriparatide
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    20 μg once daily · subcutaneousAs given in this study (human).

    Measurements

    Fractures healed at 8 weeks
    4 fractures
    control group

    Source sentences

    Summary
    At 8 weeks, all fractures in the teriparatide treatment group and 4 fractures in the control group had healed.
    3 context sentences
    Summary · context
    This retrospective, case-controlled, single center study, performed from 2009 to 2014, included 41 patients who underwent radiographs, magnetic resonance imaging, and/or bone scans to document sacral insufficiency fractures.
    Summary · context
    The intervention involved teriparatide at a once-daily subcutaneous dose of 20 μg within 2 days of hospital admission (21 patients).
    Summary · context
    Twenty patients (control group) did not receive teriparatide.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    22 Oct 2026, 02:26 UTC

    Study results updated

  2. Version 1

    21 Oct 2026, 18:59 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.